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Abstract 
The acute and chronic oral toxicity studies of antiretroviral regimens were evaluated in albino rats. For chronic 
toxicity study, the antiretroviral drugs were administered singly and in combination (CMB). Lamivudine® 
(3TC), Zidovudine® (AZT) and Nevirapine® (NVP) at single doses of 5000 mg/kg each produced treatment 
related signs of toxicity in tested animals during the first few hours but returned to normal after 48 hours 
therefore the 48 hours LD50 of each drug was estimated to be more than 5000 mg/kg. Chronic toxicity showed 
an initial percentage increase in weight between 0-6 weeks and a corresponding decrease in weight from 6-13 
weeks was observed. There was no significant (P>0.05) change in serum electrolyte levels in the treated groups 
when compared to the control group. Aspartate transaminase (AST) was significantly (P<0.05) increased in 
groups administered with 3000 mg/kg of CMB, 4000 mg/kg of CMB and at all administered doses of NVP.  
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Similarly all administered doses of NVP caused a significant (P<0.05) increase in the level of 5’ nucleotidase 
(5’NT). At administered doses of 2000 mg/kg and 4000 mg/kg body weight, NVP caused a significant (p<0.05) 
increase in total cholesterol (TC) upon comparison with the control. Administered doses of CMB and NVP, 
except at 1000 mg/kg body weight respectively, showed a significant (p<0.05) increase in the level of 
malondialdehyde (MDA) when compared with the control group. Catalase activity recorded a significant 
(P<0.05) decrease at doses of 3000 mg/kg and 4000 mg/kg body weight of CMB and NVP. Histopathological 
examination of the liver showed changes in the treated group when compared with the control group. These 
changes were corroborated by the non-invasive results. The above results indicate that NVP was the potent 
hepatotoxic agent, followed by CMB, AZT and 3TC. The hepatotoxicity was also dose dependent. 
Keywords: Antiretroviral regimen; Antioxidants; Hepatotoxic; Histopathology; Lipid profile; 5’-nucleotidase 
1. Introduction  
Acquired Immune Deficiency syndrome (AIDS) has been defined as a disease of the human immune system 
caused by the human immunodeficiency virus (HIV). An individual can also be said to be infected with HIV if 
he has a CD4+ T-cell count below 200cells/µl [1,2].AIDS progressively reduces the effectiveness of the 
immune system and leaves individuals susceptible to opportunistic infections and tumors [3,4]. A clinical 
diagnosis of HIV may be made based on the presenting symptoms and signs but many of these are non-specific 
hence the need for accurate and specific techniques. There are two major assay methods for diagnostic testing of 
HIV infection. These testing methods are virological testing and serological testing [5,6].  
The origin of HIV/AIDS has been a subject of controversy among scientists [7,8]. Numerous theories have been 
put forward regarding this subject. These theories can be separated into two major groups. The first group 
proposed that HIV/AIDS is man-made while the other proposed that the virus arose out of genetic 
modifications. The discovery of the causative agent of AIDS (HIV virus) in 1983 was credited to Luc 
Montagnier. The first documented case of AIDS occurred in the U.S.A. in the early 1980s [9,2]. 
AIDS as a pandemic has been spreading geographically [10]. NACA (National Agency for the Control of AIDS) 
estimates that 2.98 million people in Nigeria are currently infected. Estimates from the Joint United Nations 
Program on HIV/AIDS (UNAIDS) show a rise of 400,000 in the number of people living with HIV/AIDS in 
Nigeria between 2001 and 2008. The prevalence of HIV showed an increase from 1.9% in 1991 to 5.8% in 
2001. There was a decline to 5.0% in 2003 and further to 4.4% in 2005 before rising to 4.6% in 2008. All the 36 
states and F.C.T have HIV prevalence above 1%. In the North-Western region, Sokoto, Zamfara and Kebbi 
States have a prevalence of 3.3%, 2.1% and 1.0% respectively [11]. 
Antiretroviral drugs are medications for the treatment of infection by retroviruses, primarily HIV. When three or 
four of such antiretroviral drugs are taken in combination, the approach is known as Highly Active 
Antiretroviral Therapy (HAART) [12]. The introduction of HAART, a cocktail of nucleoside and non-
nucleoside analogues capable of inhibiting reverse transcriptase and protease has led to well documented 
reductions in the risk of AIDS related mortality. A survey carried out by UNAIDS in 2010 showed a reduction 
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in the number of deaths due to AIDS-related causes. In 2010 alone, 700,000 AIDS-related deaths were averted 
due to the introduction of HAART [13]. 
Toxicity studies are usually carried out to determine the dosage at which the effects of a substance are toxic, 
non-toxic or beneficial. In this research, the toxicological effects (biochemical and histopathological) of 
antiretroviral regimens when administered to rats over a long period was studied extensively. Furthermore the 
drugs were administered in single and combined doses after their LD50 had been determined. In the chronic 
toxicity studies carried out, the average weight change of the animals over the administration period was also 
recorded.  
The advent of HAART can be said to be a two-sided coin. On one side are the numerous benefits it has offered 
the world in its fight against a deadly virus. On the other side are the problems it poses to the HIV-infected 
individuals. These problems, whether real or perceived have diminished the earlier enthusiasm generated by 
HAART and has raised in its place a state of fear and confusion [14]. The purpose of this study is to evaluate the 
toxicity profiles of antiretroviral regimens which are currently part of the HAART cocktail in order to determine 
whether they are toxic or non-toxic despite being beneficial.   
This study was designed to give valid answers to the following questions:  
• What is the LD50 of the antiretroviral drugs? 
• Are the drugs toxic or non-toxic when administered over a long period of time? 
• When administered as a monotherapy, which of the antiretroviral regimens is the most toxic, moderately 
toxic and least toxic?  
• When administered as a combination therapy, are the toxicological effects ameliorated? 
• Which is the safest combination? 
Over the years, the number of deaths resulting from HIV/AIDS has fallen dramatically [15]. Thanks to 
antiretroviral treatment, more people are now living with HIV. At the end of 2010, an estimated 34 million 
people were living with HIV worldwide, up 17% from 2001[13]. The benefits that have been derived from the 
use of HAART have been numerous. Some of these include decreased mortality and morbidity among HIV-
infected patients [16,17]. The emergence of HAART has also helped in prevention of mother to child 
transmission (PMTCT) [18]. However certain issues such as antiretroviral toxicity and resistance have led to 
impaired compliance and premature discontinuation of HAART among HIV-infected individuals. 
Reports have associated HAART with toxicities amongst which are nephrotoxicity, hepatotoxicity and 
mitochondrial toxicity. These toxicities may impair patients’ adherence to treatment thus compromising viral 
control [19,20,21]. More light has to be shed on this issue in order to remove doubt, fear and a deep feeling of 
uncertainty in the infected patients regarding the safety of these drugs. Some HIV-infected individuals 
especially in the developing countries have turned to the use of herbal remedies which may have more adverse 
effect on their already endangered health especially in the advent of a drug-drug interaction and other unknown 
side-effects.It is therefore paramount that research be carried out in establishing the safety of these drugs.  
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To the best of my knowledge, there are few reports on chronic toxicity profiles of HAART. The current study 
therefore, evaluates the in vivo acute and chronic effects of antiretroviral agents, singly and in combination, on 
liver and kidney parameters of albino rats. It also evaluates the in vivo chronic effects of selected antiretroviral 
drugs (HAART) singly and in combination on serum lipid profiles and oxidative stress markers using albino 
rats. Assay of 5’-nucleotidase amongst other liver function markers was carried out. Assay of 5’-nucleotidase 
has been reported to be one of the best enzyme indices of liver damage because of its specificity [22,23]. In 
addition, the liver and kidney tissues were examined histopathologically as a means of knowing if there was 
tissue damage and the extent of the damage.  
2. Materials and Methods 
All chemicals and reagents used for this study were of analytical grade. The antiretroviral drugs used for the 
study were obtained from the Anti-AIDS Pharmacy, Usmanu Danfodiyo University Teaching Hospital, Sokoto, 
Nigeria. Zidovudine was manufactured by Cipla Ltd, Verna Industrial Estate, Goa, India with Batch No: 
X11241; nevirapine was manufactured by Aurobindo Pharma Ltd, Andhra Pradesh, India with National Agency 
for Food Drug Administration and Control (NAFDAC) reg No: 04-7679 and lamivudine was manufactured by 
Hetero Drugs Ltd, Hyderabad, India Batch No: E110243B. These are the components of HAART cocktail 
prescribed and recommended for HIV-infected persons in Sokoto State. 
A total of one hundred and forty-four (144) albino rats (wistar strain) of either sex were used in the research and 
were obtained from the Animal House, Department of Biological Science, Usmanu Danfodiyo University 
Sokoto. The animals were kept in metal cages in a well ventilated room and allowed to acclimatize for fourteen 
(14) days. They were allowed free access to clean water and feed ad libitum throughout the experiment, except 
for the short fasting period where the drinking water was still in free access but no food supply was provided 
twelve (12) hours prior to the treatment.      
Acute Oral Toxicity was performed using the up and down procedure of the organisation for economic and 
cultural development [24]. This procedure involves the limit Test, which was also used for the selection of a 
starting dose as well as determination of LD50ofthe testing material.For chronic toxicity study, one hundred and 
twenty-four (124) rats were weighed and subsequently divided into four (4) treatment groups. Members of each 
treatment group were further divided into four sub-groups (n= 6-9 rats per group). Each group was labeled to 
represent the drug to be administered. The animals in group 1 received distilled water as placebo. Animals in 
group 2 were administered a combination therapy (CMB) of lamivudine, zidovudine and nevirapinewith each 
subgroup administered 20%, 40%, 60% and 80% LD50 of CMBrespectively. Group 3, 4 and 5 animals were 
administered  nevirapine (20%,40%,60% and 80% LD50 of nevirapine), lamivudine (20%,40%,60% and 80% 
LD50 of lamivudine) and zidovudine (20%,40%,60% and 80% LD50 of zidovudine) respectively. 
The doses of the regimens were calculated based on the body weight of the animals. The drugs were 
administered in 1ml distilled water via a standard orogastric cannula for 90 days to represent chronic dosing. 
This helped in studying the long-term effects of the drugs. The body weight changes were monitored throughout 
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the experimental period weekly and the percentage change in body weight on the sixth (mid-period) and 
thirteenth week (concluding period) was calculated. 
Percentage change in weight = Final weight – Initial weight    X  100              
                                                              Initial weight 
The rats were anaesthetized by dropping each of the animals successively in a transparent plastic jar saturated 
with chloroform vapour. The animals were removed from the jar and blood samples were collected through 
cardiac puncture. The blood samples were allowed to clot for 30 minutes, before centrifugation for 10 minutes at 
500g and the serum collected was used for biochemical assays including assessment of serum 5’-nucleotidase 
enzyme activity.  
Subsequently the animals were sacrificed by decapitation; the organs (liver and kidney) were removed. They 
were perfused with cold saline to completely remove all the red blood cells. One gram (1g) portion of each liver 
was used to prepare homogenate in ice cold potassium chloride (KCl) solution (0.86 %). The required amount 
was weighed and homogenized using Teflon homogenizer. The homogenate was centrifuged at 700g for 10 
minutes to remove the nuclear fraction. The supernatant was used for the estimation of antioxidant enzymes, 
gluthathione reductase, superoxide dismutase and catalase. The level of lipid peroxidation was determined by 
estimation of malondialdehyde content by measuring the concentration of thiobarbituric acid reacting substrate 
(TBARS) in the liver homogenate. 
The following liver function tests were determined. Serum 5’-nucleotidase (5’-NT) activity was determined 
using Bertrand- Buret method [25] while colorimetric method of Sood [26] was used for measurement of serum 
alkaline phosphatase activity. Serum alanine aminotransferase (ALT) activity and serum aspartate 
aminotransferase (AST) activity were determined using Reitman-Frankel method [27]. To determine the total 
protein in the blood, the biuret method of Gomall and his colleague [28] was employed. In addition, the dye 
binding technique utilizing bromocresol green (BCG) as modified by Doumas and his colleagues[29] was 
employed in the determination of serum albumin concentration (ALB).Colorimetric method by Jendrassik and 
Grof [30] was employed for determination of serum total and conjugated (direct) bilirubin concentration. 
The following methods were used for kidney function tests. Serum urea was determined by Diacetyl monoxime 
Method using thiosemicarbazide [31] while colorimetric method with deproteinization was used in the 
determination of serum creatinine [32].Sodium and potassium concentration were determined using flame 
photometer [33]. Furthermore serum chloride was determined by colorimetric method [34]. 
Total cholesterol was determined using Trinder’s method while colorimetric method of Tietz was used for 
measurement of serum triglyceride level [35,34]. HDL cholesterol level was determined using the method 
described by Lopez-Virella et al [36]. A TBARS (thiobarbituric acid reactive substance) assay was used for the 
quantification of the end product of lipid peroxidation, to be specific, malondialdehyde (MDA)[37].The alloxan 
“305” method of Patterson and Lazarow [38] was modified and used for determination of glutathione while 
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enzymic assay of catalase was carried out by the method described by [39]. Superoxide dismutase activity was 
assayed by the method of McCord and Fridovichwith some modifications [40]. 
Three animals from each group were selected randomly, dissected through a central abdominal incision. The 
liver and kidney samples were collected and immediately fixed in 10% formal-saline in labeled plastic bottles. 
The tissues were dehydrated in graded concentrations of xylene, embedded in molten paraffin wax and 
sectioned at 5µ. Tissue sections were fixed on glass slides and stained with hematoxylin and eosin for light 
microscopy at 400X [41]. Photomicrographs of some of the tissues were taken using a microscope fitted with a 
camera unit.    
3. Results 
The results were presented as Mean ± Standard Deviation of the mean. The results were analysed using 
Bonferroni’s multiple comparison test. Values with P-values less than 5% were considered significant. 
GraphPad InStat software (San Diego U.S.A) was employed for the analysis.In the limit test, the animals in the 
control group exhibited normal signs and behavior. The breathing and heart beat was normal while they 
remained active throughout the course of the study. In contrast, the nevirapine-administered animals refused 
taking food or water and they remained inactive for six (6) hours following administration of a test dose of 5000 
mg/kg. Normal activity was observed after six (6) hours as shown in Table 1. No mortality was observed for 48 
hours. Thus the LD50 of nevirapine is greater than the test dose (5000 mg/kg). 
After administration of 5000 mg/kg of lamivudine to the animals, there was refusal of food and water for an 
hour after which normal activity was observed as shown in Table 2. No mortality was observed for 48 hours. 
Thus the LD50 of lamivudine is greater than the test dose (5000 mg/kg).Likewise, following administration of 
5000 mg/kg of zidovudine to the animals, there was refusal of food and water for two hours initially. There was 
also an increased rate of heart beat but these changes were back to normal after (2) two hours as shown in Table 
3. No mortality was observed for 48 hours. Thus the LD50 of zidovudine is greater than the test dose (5000 
mg/kg). 
The effect of oral administration of the antiretroviral regimens on the ratio of organ weight: body weight, organ 
body index as well as percentage change in body weight on the sixth and thirteenth week are shown in Table 4. 
Administration of CMB resulted in significant increase in the ratio of kidney weight: body weight when 
compared with the control group. However, only a higher dose of 3000mg/kg had a significant (p<0.05) effect 
on the ratio of liver weight: body weight. There was also a significant (p<0.05) increase in percentage weight 
gain at 6 weeks with the exception of 2000mg/kg body weight of CMB. Higher doses of NVP had no significant 
(p<0.05) effect on the ratio of liver to body weight. However there was a significant (P< 0.05) increase in the 
percentage weight gain at 6 weeks. There was also a decrease in the percentage weight loss from 6 to 13 weeks 
although the change was not significant when compared with the control. On the other hand, the lowest 
administered doses of 3TC had no significant effect on any of the above parameters. This was also observed 
with the lower administered doses of 1000mg/kg and 2000mg/kg body weight of AZT respectively. 
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Table 1. General appearance and behavioral observation for control and nevirapine® treated groups 
Observation 
Control   Treatment 
1hr 2hrs 4hrs 6hrs      
48 
hrs 
14 
days  1hr 2hrs 4hrs 6hrs 
48 
hrs 
14 
days 
Food/water 
refusal Absent Absent Absent Absent Absent Absent  Present Present Present Present Absent Absent 
Aggressiveness Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Eyes and ears Normal Normal Normal Normal Normal Normal  Normal Normal Normal Normal Normal Normal 
Convulsions Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Salivation Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Activity Active Active Active Active Active Active  Inactive Inactive Inactive Inactive Active Active 
Breathing Normal Normal Normal Normal Normal Normal  Fast Fast Fast Normal Normal Normal 
Heart beat Normal Normal Normal Normal Normal Normal  Fast Fast Fast Normal Normal Normal 
Diarrhea Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Coma Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Injury Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Mortality No No No No No No   No No No No No No 
 
Table 2. General appearance and behavioral observation for control and lamivudine® treated groups 
Observation 
Control   Treatment 
1hr 2hrs 4hrs 6hrs      
48 
hrs 
14 
days  1hr 2hrs 4hrs 6hrs 
48 
hrs 
14 
days 
Food/water 
refusal Absent Absent Absent Absent Absent Absent  Present Absent Absent Absent Absent Absent 
Aggressiveness Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Eyes and ears Normal Normal Normal Normal Normal Normal  Normal Normal Normal Normal Normal Normal 
Convulsions Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Salivation Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Activity Active Active Active Active Active Active  Inactive Active Active Active Active Active 
Breathing Normal Normal Normal Normal Normal Normal  Fast Normal Normal Normal Normal Normal 
7 
 
 International Journal of Sciences: Basic and Applied Research (IJSBAR)(2014) Volume 13, No  2, pp 1-30  
Heart beat Normal Normal Normal Normal Normal Normal  Fast Normal Normal Normal Normal Normal 
Diarrhea Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Coma Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Injury Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Mortality No No No No No No   No No No No No No 
 
Table 3. General appearance and behavioral observation for control and zidovudine® treated groups 
Observation 
Control   Treatment 
1hr 2hrs 4hrs 6hrs      
48 
hrs 
14 
days  1hr 2hrs 4hrs 6hrs 
48 
hrs 
14 
days 
Food/water 
refusal Absent Absent Absent Absent Absent Absent  Present Present Absent Absent Absent Absent 
Aggressiveness Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Eyes and ears Normal Normal Normal Normal Normal Normal  Normal Normal Normal Normal Normal Normal 
Convulsions Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Salivation Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Activity Active Active Active Active Active Active  Inactive Inactive Inactive Inactive Active Active 
Breathing Normal Normal Normal Normal Normal Normal  Fast Fast Normal Normal Normal Normal 
Heart beat Normal Normal Normal Normal Normal Normal  Fast Fast Normal Normal Normal Normal 
Diarrhea Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Coma Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Injury Absent Absent Absent Absent Absent Absent  Absent Absent Absent Absent Absent Absent 
Mortality No No No No No No   No No No No No No 
 
Table 5 presents the effect of oral administration of antiretroviral regimens on serum sodium ion, potassium ion, 
chloride ion, urea, creatinine and uric acid. Only the higher doses of NVP at 3000mg/kg and 4000 mg/kg body 
weight caused increased serum urea and creatinine significantly (p<0.05) when compared with the control. 
However, there was a significant (p<0.05) decrease in the level of serum creatinine at 4000 mg/kg body weight 
of AZT. This dose also had a significant (p<0.05) effect on the serum uric acid level when compared with the 
control. 
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Table 4. Effect of oral administration of antiretroviral regimens on the ratio oforgan weight: bodyweight of rats 
and percentage change in bodyweight of rats 
Group(N) Kidney: Body Wgt Liver: Body Wgt 
Change in Body 
Wgt at 6 wks (%) 
Change in Body 
Wgt at 13 wks 
(%) 
CONTROL(8) 0.0016±0.0003 0.018±0.002 12.1±6.3 10.0±4.9 
CMB 20(5) 0.0027±0.0007* 0.032±0.008 55.5±32.2* -1.1±9.1 
CMB 40(4) 0.0034±0.0006* 0.039±0.007 35.3±7.5 -12.9±3.0* 
CMB 60(5) 0.0034±0.0006* 0.040±0.016* 62.0±5.3* -14.7±13.9* 
CMB 80(5) 0.0027±0.0005* 0.035±0.008 56.5±21.9* -10.1±12.3* 
NVP 20(4) 0.0027±0.0007* 0.029±0.004 33.1±9.3 5.0±5.1 
NVP 40(4) 0.0033±0.0004* 0.036±0.009 17.3±8.2 -5.4±4.5 
NVP 60(5) 0.0020±0.0003 0.030±0.009 50.1.±14.4* -1.5±12.8 
NVP 80(4) 0.0020±0.0005 0.030±0.009 61.3±23.2* -9.5±8.3 
3TC 20(5) 0.0020±0.0003 0.020±0.009 38.8±9.7 6.5±8.2 
3TC 40(5) 0.0020±0.0004 0.020±0.004 31.8±13.7 -3.4±12.0 
3TC 60(4) 0.0030±0.0002* 0.040±0.006* 25.8±7.0 -0.2±2.6 
3TC 80(3) 0.0030±0.0003* 0.030±0.005 12.56±10.0 1.3±8.9 
AZT 20(5) 0.0020±0.0003 0.019±0.004 36.2±17.3 5.9±8.4 
AZT 40(5) 0.0020±0.0001 0.019±0.004 57.4±11.3* 2.2±3.0 
AZT 60(4) 0.0030±0.0006* 0.027±0.005 23.0±11.7 2.9±14.9 
AZT 80(5) 0.0020±0.0004 0.021±0.006 29.2±12.4 -2.9±9.8 
Values are expressed as mean ± S.D. The level of significance was set at *P<0.05 when compared with control at 0 mg/kg body weight 
 
The effect of oral administration of antiretroviral regimens on some serum enzyme indices in rats is shown in 
Table 6. All doses of administered nevirapine caused a significant (p<0.05) increase across all the parameters 
when compared with the control. CMB administered group at 3000 mg/kg and 4000 mg/kg body weight also 
caused a significant (p<0.05) increase across all parameters as well when compared with the control group.  
With the exception of ALP, there was a significant (p<0.05) increase in AST, ALT and 5’- NT upon 
administration of 3000 mg/kg body weight of AZT upon comparison with the control. However all parameters 
showed significant (p<0.05) increase at an administered dose of 4000 mg/kg body weight of AZT. Furthermore, 
it was observed from the result that 3TC at all administered doses showed no significant (p>0.05) increase in 
ALP and 5’-NT when compared with the control. 
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Table 5.  Effect of oral administration of antiretroviral regimens on some kidney function parameters in rats 
GROUP(N) 
Na+  
(mmol/l) K+  (mmol/l) Cl-  (mmol/l) 
Urea 
(mmol/l) 
Creatinine 
(mg/dl) 
Uric Acid 
(mg/dl) 
CONTROL(8) 140.8±2.3 4.7±0.7 98.6±2.6 6.4±0.8 0.7±0.01 4.0±0.62 
CMB 20(5) 138.2±5.5 4.8±0.6 105.6±4.9 6.8±1.1 0.8±0.10 4.1±1.28 
CMB 40(4) 140.8±3.9 4.5±0.7 108.8±2.9 7.9±0.3 1.0±0.19 4.3±2.44 
CMB 60(5) 136.8±7.6 5.1±0.8 100.8±1.5 7.6±1.1 0.8±0.10 5.4±0.99 
CMB 80(5) 140.8±3.2 4.7±0.8 97.4±9.1 8.4±1.2 1.0±0.17 5.1±1.01 
NVP 20(4) 137.5±7.2 4.5±0.7 90.3±8.8 7.7±0.3 0.9±0.09 3.2±1.90 
NVP 40(4) 137.3±8.7 4.5±0.7 93.5±5.3 8.4±0.5 1.0±0.20 4.1±0.24 
NVP 60(5) 135.0±11.4 4.6±0.7 94.2±11.2 9.8±1.4* 1.2±0.34* 4.5±0.64 
NVP 80(4) 141.0±3.0 4.9±0.7 94.0±3.5 11.3±1.5* 1.6±0.22* 6.4±0.47 
3TC 20(5) 139.6±3.9 4.0±0.4 108.8±7.0 7.1±1.1 0.7±0.04 4.4±0.52 
3TC 40(5) 139.0±6.8 5.0±0.7 99.4±5.2 7.8±0.4 0.7±0.04 4.1±1.50 
3TC 60(4) 138.0±2.6 4.2±0.8 105.8±10.0 8.0±2.0 0.8±0.08 4.4.±0.66 
3TC 80(3) 139.7±7.6 4.7±0.5 99.3±5.9 8.0±0.6 1.0±0.29 6.8±1.46 
AZT 20(5) 137.6±7.6 4.6±0.6 93.4±4.1 7.2±0.9 0.8±0.11 3.5±2.90 
AZT 40(5) 141.0±2.7 4.2±0.7 92.0±10.6 8.1±1.6 0.8±0.17 4.7±3.12 
AZT 60(4) 142.8±1.7 4.3±0.3 104.0±4.8 8.1±0.8 0.9±0.18 6.4±1.64 
AZT 80(5) 141.2±2.9 4.7±0.7 94.2±3.0 7.7±2.3 0.3±0.24* 8.0±1.05* 
Values are expressed as Mean ± SD. The level of significance was set at *P<0.05 when compared with control at 0 mg/kg body weight 
 
Table 6. Effect of oral administration of antiretroviral regimens on some serum enzyme indices in rats 
GROUP(N) AST ( U/l) ALT (U/l) ALP (U/l) 5' NT (U/l) 
CONTROL(8) 11.9±1.2 4.4±0.5 175.6±33.7 36.0±9.5 
CMB 20(5) 13.1±1.5 7.1±0.7* 234.4±47.8 138.2±5.5 
CMB 40(4) 15.0±1.1* 9.3±1.0* 255.7±49.3 56.3±8.5* 
CMB 60(5) 16.9±0.5* 10.9±0.3* 348.7±102.5* 78.0±11.8* 
CMB 80(5) 21.4±1.5* 12.6±0.6* 438.9±54.9* 90.2±8.7* 
NVP 20(4) 16.8±0.6* 10.1±1.2* 330.7.6±78.2* 74.0±9.5* 
NVP 40(4) 21.5±1.6* 13.3±0.3* 443.0±39.6* 109.7±10.5* 
NVP 60(5) 23.4±2.4* 14.7±0.5* 499.1±117.1* 129.2±10.5* 
NVP 80(4) 25.8±1.0* 15.9±1.6* 612.6.6±27.2* 145±7.0* 
3TC 20(5) 12.7±1.3 5.6±1.6 198.8±9.9 39.6±3.9 
3TC 40(5) 14.8±0.7* 8.3±0.9* 204.3±10.0 42.3±0.3 
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3TC 60(4) 15.7±0.9* 10.5±0.4* 258.5±73.0 55.5±6.6 
3TC 80(3) 18.6±2.4* 11.2±0.3* 297.4±92.4 62.6±12.0 
AZT 20(5) 12.6±1.5 8.0±3.1* 201.0±18.1 34.8±9.1 
AZT 40(5) 13.8±0.9 10.9±0.4* 233.3±41.8 59.8±10.4* 
AZT 60(4) 17.1±0.8* 12.1±1.1* 300.8±35.1 84.4±29.4* 
AZT 80(5) 18.9±1.1* 14.1±0.6* 344.7±70.4* 98.7±9.5* 
Values are expressed as Mean ± SD. The level of significance was set at *P<0.05 when compared with control at 0 mg/kg body weight. 
The effect of oral administration of antiretroviral drugs on serum non-enzyme indices is shown in Table 7. 
Nevirapine administered at 2000 mg/kg, 3000 mg/kg and 4000 mg/kg body weight caused significant (p<0.05) 
decrease in the level of total protein and significant (p<0.05) increase in total bilirubin level when compared 
with the control group. CMB and AZT at all administered doses had no significant (p>0.05) effect on albumin 
and direct bilirubin upon comparison with the control group. However, oral administration of lamivudine at 
4000 mg/kg body weight caused a significant (p<0.05) increase in total bilirubin. Other administered doses of 
lamivudine showed no significant (P>0.05) effect across all parameters when compared with the control. 
Table 7.  Effect of oral administration of antiretroviral regimens on serum non-enzyme indices in rats 
GROUP(N) Total Protein (g/dl) Albumin (g/dl) 
Total Bilirubin 
(mg/dl) 
Direct Bilirubin 
(mg/dl) 
CONTROL(8) 14.7±1.0 4.4±1.2 0.15±0.05 0.023±0.01 
CMB 20(5) 13.9±0.5 3.5±0.4 0.26±0.04 0.054±0.02 
CMB 40(4) 13.2±1.0 3.5±0.5 0.31±0.03 0.078±0.02 
CMB 60(5) 11.1±0.8* 3.1±0.2 0.47±0.04* 0.083±0.02 
CMB 80(5) 7.3±0.3* 3.0±0.3 0.64±0.20 0.110±0.04 
NVP 20(4) 14.2±1.6 3.1±0.3 0.34±0.05 0.005±0.03 
NVP 40(4) 9.7±2.5* 3.0±0.4 0.80±0.07* 0.100±0.02 
NVP 60(5) 7.0±0.5* 3.1±0.5 1.03±0.20* 0.080±0.03 
NVP 80(4) 5.4±0.6* 1.8±0.4* 1.65±0.50* 0.350±0.43* 
3TC 20(5) 13.6±2.2 4.8±0.2 0.28±0.06 0.004±0.02 
3TC 40(5) 13.6±1.6 4.1±1.1 0.45±0.06 0.005±0.03 
3TC 60(4) 11.2±0.8 4.0±0.3 0.43±0.12 0.004±0.05 
3TC 80(3) 11.5±1.3 3.1±1.1 0.73±0.01* 0.009±0.02 
AZT 20(5) 13.3±1.3 4.4±1.0 0.28±0.07 0.003±0.02 
AZT 40(5) 13.0±1.8 2.9±0.7 0.42±0.20 0.005±0.05 
AZT 60(4) 10.3±0.7* 3.0±1.0 0.57±0.10* 0.006±0.03 
AZT 80(5) 8.1±1.5* 2.7±1.1 0.98±0.10* 0.006±0.06 
Values are expressed as Mean ± SD. The level of significance was set at *P<0.05 when compared with control at 0 mg/kg body weight 
 
11 
 
 International Journal of Sciences: Basic and Applied Research (IJSBAR)(2014) Volume 13, No  2, pp 1-30  
Table 8 presents the effect of oral administration of antiretroviral regimens on serum lipid profile. It was 
observed that NVP had no significant (p>0.05) effect on LDL and HDL: LDL when compared with control. At 
2000 mg/kg and 4000 mg/kg body weight, NVP caused a significant (p<0.05) increase in total cholesterol upon 
comparison with the control. Furthermore, nevirapine had a significant effect on vLDL cholesterol at all doses. 
However at an administered dose of 1000 mg/kg body weight, nevirapine caused no significant (p>0.05) effect 
on total cholesterol, triglyceride and HDL cholesterol when compared with the control. 
Lamivudine at all doses administered had no significant (p>0.05) effect across all parameters. Also, zidovudine 
had no significant (p>0.05) effect on the level of triglyceride, HDL cholesterol, LDL cholesterol, vLDL 
cholesterol and HDL: LDL at all administered doses. At administered doses of 1000 mg/kg, 2000 mg/kg and 
3000 mg/kg body weight, CMB had no significant (p>0.05) effect across all parameters when compared with 
the control group. 
 
Table 8. Effect of Oral Administration of Antiretroviral Regimens on Serum Lipid Profiles in Rats 
GROUP(N) 
Total Chol 
(mg/dl) 
Triglyceride 
(mg/dl) 
HDL Chol 
(mg/dl) 
LDL Chol 
(mg/dl) 
vLDL 
Chol 
(mg/dl) 
HDL: 
LDL 
CONTROL(8) 99.1±12.9 112.0±14.2 72.0±9.1 11.0±13.3 22.4±2.8 4.0±5.1 
CMB 20(5) 118.8±16.2 96.0±25.3 99.4±16.4 11.4±12.5 19.2±5.1 3.8±4.6 
CMB 40(4) 139.0±21.3 70.0±17.7 107.0±35.4 20.6±13.8 14.0±3.6 2.5±1.6 
CMB 60(5) 162.8±18.7 78.0±30.2 124.0±14.1 23.2±18.8 15.6±6.0 14.2±18.2 
CMB 80(5) 230.8±29* 56.0±18.8* 161.4.±19.2* 45.4±40.1 11.2±3.8* 9.3±10.3 
NVP 20(4) 143.5±39.6 58.0±20.0 116.3±15.5 24.9±42.4 8.9±3.7* 3.0±5.2 
NVP 40(4) 206.5±50.4* 56.0±17.3* 132.0±21.3 69.3±50.7 11.2±3.5* 1.0±0.7 
NVP 60(5) 187.6±55.7* 59.2±25.0* 162.2±22.6* 30.8±35.1 11.8±5.0* 2.3±2.9 
NVP 80(4) 287.0±24.1* 38.0±13.7* 236.0±65.3* 43.5±48.7 7.6±2.7* 15.2±27.5 
3TC 20(5) 109.4±19.3 94.4±20.7 74.6±33.0 25.9±17.6 18.9±4.1 1.8±1.5 
3TC 40(5) 91.6±15.4 107.2±22.3 96.0±51.5 2.6±6.0 21.4±4.5 - 
3TC 60(4) 119.5±18.6 92±15.3 73.5±34.3 39.9±26.9 18.4±3.1 0.8±0.6 
3TC 80(3) 174.3±29.6 59.3±12.1 87.3±44.7 76.3±73.0 11.9±2.4 0.4±0.5 
AZT 20(5) 114.4±37.6 105.6±22.2 67.0±13.5 29.7±40.3 21.1±4.4 6.5±10.9 
AZT 40(5) 113.6±19.2 99.2±36.9 81.8±19.7 20.7±18.2 19.8±7.4 4.9±7.1 
AZT 60(4) 176.0±6.3* 100.0±33.0 73.3.±11.9 82.8±14.1 20.0±6.6 0.9±0.3 
AZT 80(5) 179.2±69.0* 99.2±36.0 97.2±28.4 57.3±72.4 19.9±7.3 4.4±7.3 
Values are expressed as Mean ± SD. The level of significance was set at *P<0.05 when compared with control at 0 mg/kg body weight. 
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The effect of antiretroviral regimens on liver enzymatic and non-enzymatic antioxidant levels is shown in Table 
9. Administered doses of CMB and NVP except at 1000 mg/kg body weight respectively caused a significant 
(p<0.05) increase in the level of MDA when compared with the control group. However there was no significant 
(p>0.05) effect in the level of reduced gluthatione at all doses of administered drugs except at 4000 mg/kg body 
weight of nevirapine. Also zidovudine at administered doses of 1000 mg/kg and 2000 mg/kg respectively 
caused no significant (p>0.05) effect across all parameters. 
Administered doses of 4000 mg/kg body weight of lamivudine caused a significant (p<0.05) decrease in catalase 
level when compared with the control group. Also 2000 mg/kg body weight of lamivudine administered orally 
caused a significant (p<0.05) decrease in the level of superoxide dismutase upon comparison with the control. 
However other administered doses of lamivudine had no significant (p>0.05) effect across all parameters when 
compared with the control. 
Table 9. Effect of oral administration of antiretroviral regimens on liver-enzymatic and non-enzymatic 
antioxidants levels in rats 
GROUP(N) MDA (nmoles /g tissue) 
Reduced Gluthatione(ng 
GSH/g tissue)x 106 Catalase (units/g tissue) 
Superoxide Dismutase 
(units/g tissue) 
CONTROL(5) 0.77±0.08 0.10±0.011 3.7±0.7 14.1±1.6 
CMB 20(5) 1.21±0.22 0.09±0.004 3.2±0.6 12.3±1.3 
CMB 40(4) 1.66±0.25* 0.08±0.015 2.1±0.4 12.2±1.7 
CMB 60(5) 2.02±0.09* 0.08±0.016 1.9±0.3* 10.0±1.8* 
CMB 80(5) 2.25±0.28* 0.07±0.011 1.2±0.5* 8.8±1.1* 
NVP 20(4) 0.86±0.09 0.09±0.006 2.6±0.7 11.9±1.6 
NVP 40(4) 1.62±0.38* 0.08±0.016 1.6±0.8* 10.2±1.3* 
NVP 60(5) 2.21±0.28* 0.06±0.009 1.3±0.7* 10.1±2.0* 
NVP 80(4) 2.59±0.46* 0.04±0.011* 0.6±0.2* 11.0±1.4 
3TC 20(5) 0.85±0.16 0.10±0.005 3.5±0.8 13.2±1.3 
3TC 40(5) 1.14±0.34 0.09±0.011 2.2±0.3 10.4±1.8* 
3TC 60(4) 0.68±0.36 0.09±0.002 2.1±0.7 13.2±1.2 
3TC 80(3) 0.76±0.42 0.09±0.013 1.6±0.4* 10.7±1.8 
AZT 20(5) 0.92±0.33 0.10±0.010 2.7±1.3 12.3±1.5 
AZT 40(5) 0.93±0.21 0.07±0.001 2.5±0.7 12.7±1.3 
AZT 60(4) 1.24±0.27 0.08±0.016 1.8±1.3* 12.2±1.4 
AZT 80(5) 2.03±0.15* 0.07±0.010 1.1±0.5* 9.2±1.9* 
Values are expressed as Mean ± SD. The level of significance was set at *P<0.05 when compared with control at 0 mg/kg 
In Fig.1, the liver of animals in the control group showed typical hepatolobular architecture while examination 
of the liver histological preparations obtained from all the experimental treated groups showed comparable 
changes as observed in Figs.2- 9. The hepatolobular architecture of the control animals shown in Fig.1 indicates 
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a normal histological appearance. The central vein (cv) in the center of the hepatic lobule is filled with blood 
(B). Hepatocytes, arranged in form of cords are rounded to polyhedral in shape and radiate peripherally. They 
also show nucleus (N) with clear nuclear membrane and nucleolus (NO). The cords are separated by sinusoids 
(S) with Kupffer cells (H&E stain, x 100). 
The photomicrographs of rats administered 1000 mg/kg and 4000 mg/kg body weight of CMB as seen in Figs. 2 
and 3 show severe distortion of the hepatic architecture. There is extensive ballooning of the hepatocytes (HB) 
and evidence of steatosis (S). Sinusoidal arrangement is also deranged (H&E stain, x 100). This distortion is 
more severe in the group administered 4000 mg/kg body weight of CMB as indicated in Fig.3 evidenced by 
necrotic areas and distorted areas in an overlapping interface (H&E stain, x 100).  
The photomicrographs of rats administered 1000 mg/kg body weight of nevirapine as seen in Fig.4 show severe 
distortion of the hepatic architecture evidenced by extensive ballooning of the hepatocytes (H&E stain, x 200). 
The distortion is more severe in the rats administered 4000 mg/kg body weight of nevirapine evidenced by 
necrotic areas and distorted areas (H&E stain, x 100). Photomicrographs of the lamivudine administered animals 
show mild and moderate distortion of the hepatic architecture with observed steatosis (S). There are preserved 
areas within the hepatic architecture. Mild distortions were also observed in groups administered 1000 mg/kg 
body weight of zidovudine as seen in Fig. 8.  It therefore appears that the pathological effect of the chronic 
administration of the antiretroviral drugs was dose-dependent.  
Chronic administration of antiretroviral drugs indicated that the histological preparations of the kidney as shown 
in Figs.11 and 12 had normal architecture when compared to the control group shown in Fig.10. Section of the 
kidney shows normal proximal (PT) and distal tube (DT), glomerulus (G), blood vessels and interstitions. 
Podocytes (P) and corpuscular space (CS) appear within normal range (H&E stain, × 100). 
 
 
 
Fig. 1. Photomicrograph of liver section of rats from control group 
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Fig. 2. Photomicrograph of liver section of rats administered 1000 mg/kg body weight 
 
 
Fig. 3. Photomicrograph of liver section of rats administered 4000 mg/kg body weight of CMB 
 
 
Fig. 4. Photomicrograph of liver section of rats administered 1000 mg/kg body weight of nevirapine 
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Fig. 5. Photomicrograph of liver section of rats administered 4000 mg/kg body weight of nevirapine 
 
 
Fig. 6. Photomicrograph of liver section of rats administered 1000 mg/kg body weight of lamivudine 
 
 
 
Fig. 7. Photomicrograph of liver section of rats administered 4000 mg/kg body weight of lamivudine 
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Fig. 8. Photomicrograph of liver section of  rats administered 1000 mg/kg bodyweight of Zidovudine 
 
 
 
Fig. 9. Photomicrograph of liver section of  rats administered 4000 mg/kg bodyweight of Zidovudine 
 
 
 
Fig. 10. Photomicrograph of kidney section of rats from control group 
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Fig. 11. Photomicrograph of kidney section of rats administered 4000 mg/kg body weight of CMB 
 
 
 
Fig.12. Photomicrograph of kidney section of rats administered 4000 mg/kg body weight of  nevirapine 
 
4. Discussion 
In screening drugs, determination of LD50 is usually an initial step in the assessment and evaluation of the toxic 
characteristics of a substance. The 48 hours LD50 is defined as the oral dose at which fifty (50) percent of the 
exposed test animals died, usually within forty-eight (48) hours (OECD, 2001). Using the OECD limit test 
procedure the LD50 of nevirapine®, lamivudine® and zidovudine® exceeded 5000 mg/kg body weight 
respectively which corresponds to low toxicity substances suitable for in vivo studies though these values are 
greater than the reported LD50 of the active pharmaceutical ingredient in each drug. This may be due to factors 
such as the concentration of the formulation (dilute or concentrated), the type of formulation (wet or dry) and 
the presence of other ingredients other than the active pharmaceutical ingredients in the formulation with greater 
LD50 value [42]. 
Acute toxicity data are of limited clinical application since cumulative toxic effects do occur even at very low 
doses. Hence chronic toxicity studies are invaluable in evaluating the safety profile of drugs [43]. In the repeated 
dose 90 days oral toxicity study, administration of the antiretroviral regimens revealed an increase in percentage 
18 
 
 International Journal of Sciences: Basic and Applied Research (IJSBAR)(2014) Volume 13, No  2, pp 1-30  
weight gain of treated animals between week 0 and week 6. This increase was significant (P<0.05) in CMB-
treated groups of 1000, 3000 and 4000 mg/kg body weight respectively when compared with the control group. 
Weight gain has been associated with the use of HAART at the initiation of therapy. This may be attributed to 
various metabolic complications of lipid/ glucose. These complications include diabetes, dyslipidemia and body 
fat changes.  
However the long term effect of these drugs is usually a significant loss in weight. This was observed after 13 
weeks of administration especially in the CMB-treated groups when compared to the control. The reason for this 
could be a modification of both fat metabolism and distribution by the NRTIs. AZT in particular has been 
reported to decrease the specific activities of cytochrome c oxidase and fatty acid synthase thus leading to a 
lowered cell lipid accumulation [44]. The presence of NRTIs especially in the CMB-treated group may be 
responsible for this weight loss.  
Ratio of organs: body weight is normally investigated to determine whether the size of the organs has changed 
in relation to the weight of the whole animal. According to Moore and Dalley [45], an increase in organ/body 
weight ratio is an indication of inflammation while a reduction in the same parameter can be adduced to cell 
shape changes and tissue movements [46]. There was an increase in the liver/body weight ratio of some of the 
treated groups when compared with the control. This increase was significant in the groups treated with 3000 
mg/kg body weight of NVP and 3TC. 
Hepatomegally observed in treated groups may be attributed to the administration of these antiretroviral drugs 
hence they should be used with caution especially in individuals with liver related diseases. Furthermore there 
was an observed increase in the kidney/body weight ratio which was significant in some treated groups. This 
increase was significant in all CMB-treated rats. This could be attributed to the effects of the administered 
combined regimen causing a decrease in osmolality evidenced by the enlarged kidney since renal function 
indices were not affected rather than as a result of their toxicological effects.  
Renal function indices are usually required to assess the normal functioning of different parts of the nephrons 
[47].  Kidney function is affected by a number of factors, which may ultimately result in its failure. Causes of 
kidney failure include destruction of the tubules in the kidney by drugs, including phytochemicals. As a result, 
the two main functions of the kidney: the glomerular filtration and tubular re-absorption and secretion may be 
affected [48]. Similarly, the serum concentrations of electrolytes could give an insight into the effect of drugs on 
the tubular and or glomerular part of the kidney. Therefore, the insignificant effect of the antiretroviral regimen 
at all the doses investigated on the concentration of electrolytes may suggest that the normal functioning of the 
nephrons at the tubular and glomerular levels were not affected by chronic administration of the drugs and their 
combination.  
The plasma concentration of creatinine is relatively constant under normal circumstances, unless Glomerulus 
Filtration Rate (GFR) changes, as a result of defective renal function, plasma concentration of creatinine is a 
good index of measuring GFR [48]. In the current work, only the highest doses of NVP and AZT caused a 
significant difference in serum creatinine concentrations of the treated animals. Though plasma urea 
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concentration is less reliable than the creatinine as an index of GFR, by virtue of the fact that it diffuses back 
into the renal tubular cells and its plasma concentration is dependent on the state of the liver function and 
protein intake and oxidation [49]. Estimation of the serum creatinine and urea complement each other in 
evaluating this function of the kidney. This fact is supported by the observation that the serum urea 
concentrations of the treated animals were also not significantly (p<0.05) different except at administered doses 
of 3000 mg/kg and 4000 mg/kg body weight of nevirapine. However, this could be as a result of dehydration 
[50]. It can be suggested that administration of the antiretroviral drugs both singly and in combination did not 
have any toxicological effect on the glomerulus filtration rate of the treated animals. 
One of the most common causes of hyperuricaemia is gout, in which there are either tophi or acute arthritis. 
Mild asymptomatic idiopathic hyperuricaemia has also been associated with hyperlipidaemia and coronary heart 
disease [49]. Hyperuricaemia as a result of chronic renal failure can be ascertained by correlating uric acid level 
with urea and creatinine. The general trend in the result of the chronic oral toxicity test in the current study 
suggests that the drugs has no effect on the serum level of uric acid except at an administered dose of 4000 
mg/kg body weight of AZT which was significantly (P<0.05) different. This may have been due to over 
hydration from excessive water intake [50]. This assertion is informed from the fact that serum urea and 
creatinine levels, which are also expected to be raised if the problem were renal, are normal.  
The liver is a vital organ involved in detoxification, protein synthesis and production of biochemicals essential 
for the process of digestion (e.g. bile). Albumin is the most abundant of the plasma proteins with the 
physiological role of maintenance of osmotic pressure, transportation of both endogenous and exogenous 
substances and serving as protein reserve. The ability of the liver to synthesize albumin is diminished if the 
synthetic function of the organ is affected [48].  Albumin synthesis is affected not only in liver disease but also 
by nutritional status, hormonal balance and osmotic pressure. The results of this study revealed a decrease in the 
serum albumin in the groups treated with CMB, NVP and AZT. This change was significant in the group treated 
with 4000 mg/kg body weight of NVP.  
The assay of serum total protein alone may not portray the true picture of the metabolic state of the individual, 
since the concentration of the individual proteins do not rise or fall in parallel with one another [48]. Increased 
plasma total protein concentration may be due to dehydration, to increased plasma immunoglobulin 
concentration due to infection. Plasma concentration of proteins may decrease as a result of over hydration, 
impaired protein synthesis due to malnutrition and liver disease amongst other factors. In the current study, the 
total protein of groups treated with 3000 mg/kg and 4000 mg/kg body weight of CMB, NVP and AZT when 
compared to the control was significantly decreased. These results demonstrate the fact that the synthetic 
function of the liver of the animals exposed to higher doses of CMB, NVP and AZT was affected. 
Bilirubin is an endogenous anion derived from hemoglobin degradation from the RBC. Bilirubin, a metabolic 
breakdown product of heme derived from senescent red blood cells, is also one of the most commonly used liver 
function tests [51]. From the results, the significant (P<0.05) increment in the total bilirubin level of groups 
treated with 3000 and 4000 mg/kg body weight of CMB, NVP and AZT could be adduced to impairment in the 
secretory function of these proteins amongst which are overproduction, defective conjugation in the hepatocyte 
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and presence of substances interfering with bilirubin-albumin binding sites. This may also adversely affect the 
functional activity of the liver. 
The expression of toxicity of xenobiotics is usually determined biochemically by monitoring of some plasma 
enzymes and lipids. Serum alanine aminotransferase (ALT) and aspartate aminotransferase (AST) are useful 
indices for identifying inflammation and necrosis of the liver [49,52]. ALT has its highest concentration in the 
liver with kidney and skeletal muscles having lesser activity of the enzyme. The activity of AST is located in the 
microsomal and mitochondrial portions of the liver cells as well as in the skin, skeletal and cardiac muscles, 
pancreas and kidney [49,48]. 
In the current study, all doses of NVP caused significant (P<0.05) changes in both AST and ALT levels when 
compared to the control and this increase was observed to be dose dependent. CMB also increased the level of 
AST and ALT significantly (P<0.05) except at a dose of 1000 mg/kg body weight. AZT also caused a 
significant increase (P<0.05) in the level of both enzymes. It may be inferred therefore that these changes may 
be due to the effect of the administered drugs. This suggests that chronic administration of antiretroviral regimen 
has hepatotoxic effects in rats. This is an indication that CMB, NVP and AZT can result in hepatic damage and 
can also lead to an increase in hepatotoxicity in patients with liver diseases.  
ALP is a liver enzyme that is usually found in the walls of the intra- and extra-biliary ducts. Increased level of 
alkaline phosphatase has been attributed to the damaged structural integrity of hepatic cells because the enzyme 
alkaline phosphatase is located in the cytoplasm and is released into the circulation after cellular damage [49]. In 
the present study, the alkaline phosphatase activities of animals treated with chronic oral doses of NVP was 
significantly different (P<0.05). At administered doses of 4000 mg/kg body weight of AZT and CMB, ALP 
levels were significantly (P<0.05) higher when compared with the control. These results may have been due to 
disturbances in the secretory activity, or in the transport of metabolites or other hepatotoxic conditions [53]. 
However it was observed that lamivudine appears to be less hepatotoxic than the other drugs. This drug is 
preferred for HIV/AIDS patients with high risk of hepatotoxicity especially those with hepatitis B or hepatitis C 
coinfection  [54]. 
5’-Nucleotidase (5’-NT) is an intrinsic membrane glycoprotein, present as an ectoenzyme in a wide variety of 
mammalian cells. 5’-NT hydrolyzes 5’-nucleotides to their corresponding nucleosides. The diagnostic value of 
5’-NT has been shown to be superior to other liver enzymes, especially in liver metastasis [55]. This research 
revealed a significant increase (P<0.05) at all doses of NVP administered to the rats. CMB also caused a 
significant (P<0.05) increase in the level of this enzyme except at 1000 mg/kg body weight. However 
administration of 3TC did not cause any significant change in the level of 5’ NT.   
Elevated activities of these liver enzymes indicate cell damage which might have resulted from several 
mechanisms; generation of toxic species, peroxidation of membranes etc. The exact mechanisms by which NVP 
and CMB causes adverse hepatic events have not been elucidated, but Lee [56] reports that drug-induced liver 
injury occurs via at least six mechanisms involving various intracellular organelles, with consequent disruption 
of intracellular calcium homeostasis, decrease in ATP levels and finally the hepatocyte get inflamed and rupture.  
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Several antiretrovirals, including AZT, have been reported to cause fatal acute hepatitis [57]. Mechanisms that 
have been suggested for AZT induced toxicity include alteration in liver mitochondrial DNA, alteration in 
oxidative phosphorylation coupling and changes in fine ultrastructure of liver mitochondrial [58]. The 
hepatotoxic effects of the antiretroviral regimens appeared to be buttressed by the histopathological findings 
from the liver tissues of the treated groups. Most of the liver slides viewed showed signs of derangement. 
Nevirapine appeared to be the most toxic while the least toxic was lamivudine. The presence of lamivudine in 
CMB may have reduced its toxicity. Most importantly, the toxicological effects of the antiretroviral drugs 
appeared to be dose-dependent.  
A lipid profile is a measure of three components: total cholesterol (TC), triglycerides (TG) and lipoproteins 
(high and low density). TC comprises all the cholesterol found in various lipoproteins such as high density 
(HDL), low density (LDL) and very low density (VLDL). HDL-cholesterol is believed to play a key role in the 
process of reverse cholesterol transport that promotes the efflux of excess cholesterol from vessel wall to the 
liver for excretion. On the contrary, LDL cholesterol is responsible for cholesterol deposit on the wall of the 
artery[59]. 
TG is the  neutral  fat  metabolite  found in  the  tissue  and  blood and  may  contribute  to  the  disorders  relate
d to coronary heart disease (CHD). 
Changes in lipid profiles due to administration of the antiretroviral regimens are illustrated in Table 8. The 
results of this study indicate that there were no significant increases in the level of LDL cholesterol across all the 
groups. The increase in total cholesterol was significant in groups treated with 3000 and 4000 mg/kg body 
weight of NVP and AZT when compared with the control. However there was a significant decrease in the TG 
level of the rats treated with 2000 mg/kg, 3000 mg/kg and 4000 mg/kg body weight of NVP. These elevated 
levels of TC may be related with the peroxidation potential of the antiretroviral drugs or impairment in the 
biosynthesis of cholesterol. Increment in the levels of TC and reduction in TG may also be related to drug-
induced lipid profile alteration and drug-induced protein metabolism [60,61]. These finding suggests that the 
antiretroviral drugs may have an effect on serum lipid profile.  
The changes in lipids and lipoproteins differ between patients using an ART regimen containing either a PI or a 
NNRTI. Whereas many of the PI-based regimens are often associated with increased levels of TG, TC and 
LDL-cholesterol, NNRTI-based regimens are associated with marked increases of HDL-cholesterol level. In this 
research, there was an increase in the level of HDL-cholesterol in all NVP and CMB-treated groups. This 
increase was significant in the groups treated with 3000 mg/kg and 4000 mg/kg body weight of NVP. Based on 
these findings, HAART regimens containing NVP may be expected to result in a reduced risk of coronary heart 
disease. The presence of NVP in the CMB-treated group may have also caused a significant (P<0.05) increase in 
the HDL-cholesterol level. This is consistent with the findings of [62] which showed a high increase in HDL-
cholesterol when NVP antiretroviral regimens were administered to HIV-infected individuals. 
The drug induced alteration in lipid profile may be correlated with its lipid peroxidation phenomenon. Drug-
induced lipid peroxidation and profile alteration can be correlated with drug-induced toxicity [60].The results of 
this research indicate an increase in the level of MDA produced in administered doses of 2000 mg/kg, 3000 
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mg/kg and 4000 mg/kg body weight of CMB and NVP respectively. This is in accordance with studies carried 
out by [63]which reported that HAART medications may increase oxidative stress levels above and beyond 
levels caused by the virus itself. It is therefore possible that the observed effect may be a consequence of this 
association. There was also an increase in AZT-treated rats in the MDA level which was significant in the group 
administered with 4000 mg/kg body weight of AZT. This may have been due to generation of reactive oxygen 
species (ROS), peroxide production and oxidative damage in mitochondria which have been reported to play 
vital roles in zidovudine-induced toxicity [64,58].  
The presence of AZT and NVP in the combined therapy may have increased the effect of CMB on the level of 
non-enzymatic antioxidants in the treated rats. Laurent et al [65] also reported that the three commonly used 
fixed-dose combination therapy for HAART therapeutic regimes used on patients (lamivudine, stavudine and 
nevirapine) lowered plasma concentration of the antioxidant Vitamin C and increased thiobarbituric acid 
reactive substances (TBARs) (a marker for lipid peroxidation). 
Oxidative stress (OS) in cells and tissues usually refers to increased generation of O2- and H2O2 which can be 
achieved by raising oxygenconcentrations in tissues or adding certain toxins that increaseintracellular oxidant 
formation or activating a large number ofphagocytes [66]. Glutathione is the major endogenous antioxidant 
produced by the cell. HAART may reduce glutathione (GSH) synthesis, enhance GSH utilization, or limit 
intracellular  reduction of its oxidized form (GSSG) consequent upon OS-mediated processes [67]. Though there 
was a decrease in the level of reduced gluthathione across the groups, it was only significant at 4000 mg/kg 
body weight of administered NVP.  
Superoxide dismutase catalyzes the reaction of superoxide anion radicals (O2-) dismutation to hydrogen 
peroxide (H2O2), whereas catalase degrades H2O2 into a molecule of oxygen and water [68]. Superoxide ion and 
hydroxyl radicals are known to cause marked injuries to the surrounding tissues and organs. Therefore removing 
superoxide ion and hydroxyl radicals is probably one of the most effective defense mechanisms against a variety 
of diseases. Catalase protects cells from oxidative stress of hydrogen peroxide by its cleavage to water and 
oxygen [69]. In this study, there was an observed decrease in the level of SOD but this was only significant at 
the highest doses of CMB and NVP. This decrease in SOD activity suggests inactivation (or overutilization) of 
the enzyme probably caused by increased superoxide radical production, or an inhibition by the hydrogen 
peroxide as a result of corresponding decrease in the activity of CAT in NVP metabolism. This could also be 
responsible for the significant decrease in catalase activity as seen in higher doses of the administered regimens. 
It may be deduced therefore that NVP, CMB and AZT are associated with adverse effect on the level of 
enzymatic antioxidants. 
Histopathology refers to the microscopic examination of tissue sections in order to study the manifestation of 
disease. The histopathology assessment in liver and kidney tissue was performed for all groups. Animals in the 
control group showed normal well defined histological structures without any signs of vascular, necrotic or 
inflammatory changes while those in the treated groups revealed signs of toxicity after administration of the 
antiretroviral regimen. These morphological changes were assessed semi-quantitatively and graded as follows: 
mild change, moderate change, severe change and severely severe.  
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The histopathological analysis of the hepatic tissue show varying degrees of changes. Lamivudine- treated 
animals had the least morphological change when compared with the control. The changes observed were mild 
and moderate. They were also less severe when compared to the NVP, CMB and AZT treated groups. 
Administration of 4000 mg/kg body weight AZT shows a greater severity of morphological changes such as 
distortion of the hepatic architecture and evidence of steatosis when compared with the lower administered 
doses. The morphological change due to the administration of AZT appears to be dose dependent.  
Nevirapine and CMB treated animals show changes ranging from severe to severely severe. Severe distortion of 
the hepatic architecture can be observed in NVP and CMB treated animals. These morphological changes also 
appear to be dose dependent. It may be deduced that these drugs are hepatotoxic upon administration. However, 
the histopathological assessment of the kidney did not reveal any vascular, necrotic or imflamatory change in 
the treated groups. Hence it can be assumed that administration of the antiretroviral drugs was not nephrotoxic. 
5. Conclusion 
From this research, it can be observed that acute administration of the antiretroviral drugs may be toxic. These 
toxicological effects are more pronounced when the drugs were administered over a longer period and they 
appear to be dose-dependent. When administered as single doses, nevirapine appeared to be the most potent 
while lamivudine seemed to be the least toxic. The presence of nevirapine and zidovudine in the combined 
therapy may have contributed to its toxicity. However it was observed that even at high doses, the antiretroviral 
drugs used in this study were non-toxic to the kidney either as single doses or combination therapy. 
Lipid profile alteration and oxidative stress were also associated with administration of these antiretroviral 
regimens. Nevirapine use as a single dose and in combined therapy was linked with increased MDA levels. This 
could have led to lipid peroxidation observed with the use of HAART. Interestingly however it was observed 
that the use of nevirapine led to an increase in HDL-cholesterol level. This may be beneficial in addressing the 
cardiovascular risks posed by the use of HAART and the HIV/AIDS disease.    
Furthermore results from this study shows that a combination of lamivudine and zidovudine will be expectedly 
less toxic than a combination of lamivudine and nevirapine. A combination of zidovudine and nevirapine will 
expectedly be the most toxic amongst any of the possible 2-pill combinations. This research has shown that the 
antiretroviral drugs used in this study are hepatotoxic though within varying degrees. In conclusion, 
administration of these drugs should be done with utmost caution in HIV-infected individuals especially those 
who are co-infected with a liver-related disease.    
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